Abstract
In considering cancer risks and strategies for their elimination it is vitally important to keep in mind the diverse nature of the disease. Not only are there many different kinds of cancer, each with subtypes, but also it seems likely that for any one cancer there may be a variety of interacting causal factors. Moreover, there is good evidence that the same cancer type may be the end result of a number of quite different causal pathways. Such considerations will have both advantages and disadvantages in trying to understand cancer. On the negative side, the sheer complexity of the causal mechanisms makes both analysis of the aetiology and proposals for preventive action extremely difficult and, of course, the existence of multiple pathways can mean that even a successful strategy may not deal adequately with all the risks. On the other hand our growing power to resolve subclasses of disease often means that we can see a causal pattern clearly for the first time even though the number of cases in that category may be small. Furthermore, the existence of multiple factors in the aetiology of a cancer, while it may make complete elucidation of mechanisms difficult, means that removal of only one of the causal factors may make a major impact in reducing incidence even in the absence of complete understanding.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
Similar content being viewed by others
References
Bagshawe KD, Rawlings G, Pike MC, Lawler SD (1971) ABO blood groups in trophoblastic neo-plasia. Lancet 1:553
Bridges BA, Harnden DG (1982) Ataxia–telangiectasia: a cellular and molecular link between cancer, neuropathology and immune deficiency
Cavanee WK, Dryja TP, Philips RA, Benedict WF, Godbout R, Gallie BL, Murphree AL, Strong LC, White RL (1983) Expression of recessive alleles by chromosomal mechanisms in retinoblas-toma. Nature 305:779–784
Cavanee WK, Hansen MF, Nordenskjold M, Kock E, Maumenee I, Squire JA, Philips RA, Gallie BL (1983) Genetic origin of mutations predisposing to retinoblastoma. Science 228:501–503
Dausset J, Colombani J, Hors J (1982) Major histocompatibility complex and cancer with special reference to human familial tumours (Hodgkin’s disease and other malignancies). Cancer Surveys 1:119–149
de Klein A, van Kessel AG, Grosveld G, Bartram CR, Hagmeijer A, Bootsma D, Spurr NK, Heis-terkamp N, Groffen J, Stephenson JR (1982) A cellular oncogene is translocated to the Philadelphia chromosome in chronic myeloid leukaemia. Nature 300:765–767
Harnden DG, Herbert A (1982) Association of constitutional chromosome rearrangements with neoplasia. Cancer Surveys 1:149–173
Harnden DG, Langlands AO, McLean N (1971) Carcinoma of the breast and Klinefelter’s syndrome. J Med Genet 8:460–61
Heighway J, Thatcher N, Cerny T, Hasleton PS (1986) Genetic predispostion to human lung cancer. Br J Cancer 53:453–57
Jeffreys A, Brookfield JFY, Semeonoff R (1985) Positive identification of an immigration test-case using human DNA fingerprints. Nature 317:818–819
Kaiser-McCaw B, Hecht F (1982) Ataxia telangiectasia: chromosomes and cancer. In: Bridges BA, Harnden DG (eds) Ataxia telangiectasia: a cellular and molecular link between cancer, neuropathology and immune deficiency. Wiley, Chichester, pp 243–257
Kennaugh A, Butterworth S, Hollis R, Baer P, Rabbits TH, Taylor AMR (1986) The chromosome breakpoint at 14q32 in an ataxia-telangiectasia t(14;14) T cell clone is different from the 14q32 breakpoint in Burkitt’s and inversion T cell lymphoma. Hum Genet (in press)
Knudson AG (1971) Mutation and cancer: statistical study of retinoblastoma. Proc Natl Acad Sci USA 68:820–823
Krontiris TG, DiMartino NA, Colb M, Parkinson DR (1985) Unique allelic restriction fragments of the human Ha-ras locus in leukocyte and tumour DNAs of cancer patients. Nature 313:369–374
Kunkel LM (1986) Analysis of deletions in DNA from patients with Becker and Duchenne muscular dystrophy. Nature 322:73–77
Lalande M, Dryja TP, Schreck J, Shipley J, Flint A, Latt SA (1984) Isolation of chromosome 13 specific DNA sequences cloned from flow sorted chromosomes and potentially linked to the retinoblastoma locus. Cancer Genet Cytogenet 13:283–296
Lynch HT, Frichot BC, Lynch JF (1977a) Cancer control in xeroderma pigmentosum. Arch Der-matol 113:193–195
Lynch HT, Lynch J, Lynch P (1977b) Management and control of familial cancer. In: Mulvihill JJ, Miller RW, Fraumeni JF (eds) Genetics of human cancer. Raven, New York
Lynch HT, Kimberling WJ, Biscone KA, Lynch JF, Wagner CA, Brennan K, Malliard JA, Johnson PS, Soori JS, McKenna PJ (1986) Familial heterogeneity of colon cancer risk. Cancer 57:2089–2096
Mann JR, Corkery JJ, Fisher HJW, Cameron AH, Mayerova A, Wolf U, Kennaugh AA, Woolley V (1983) The X-linked recessive form of XY gonadal dysgenesis with a high incidence of gonadal germ cell tumours: clinical and genetic studies. J Med Genet 20:264–270
McConnell RB (1966) The genetics of gastrointestinal disorders. Oxford University Press, London
McKusick VA (1983) Mendelian inheritance in man, 6th edn. John Hopkins, Baltimore
Miller RW (1970) Neoplasia and Down’s syndrome. Ann NY Acad Sci 171:637–644
Mulvihill JJ (1981) Cancer control through genetics. In: Arrighi FE, Rao PN, Stubblefield E (eds) Genes, chromosomes and neoplasia. Raven, New York
Mulvihill J, Wade WM, Miller RW (1975) Letter: gonadoblastoma in dysgenetic gonads with a Y chromosome. Lancet 1:863
Ponder BAJ (1984) Role of genetics and familial factors. In: Stoll BA (ed) Risk factors and multiple cancer. Wiley, Chichester, pp 177–204
Ramsay CA, Coltart TM, Blunt S, Pawsey SA (1974) Prenatal diagnosis of xeroderma pigmen-tosum, report of the first successful case. Lancet 2:1109
Ray JH, German J (1981) In: The chromosome changes in Bloom’s syndrome, ataxia-telangiectasia, and Fanconi’s anaemia. Raven, New York, pp 351–378
Riccardi VM, Hittner HM, Francke U, Yunis JJ, Ledbetter D, Borges W (1980) The aniridia-Wilm’s tumour association; the critical role of chromosome band 11pl3. Cancer Genet Cyto-genet 2:131
Sjoqvist F (1985) Interindividual differences in drug responses: an overview. In: Rowland M, Steiner LB, Steiner JL (eds) Variability in drug therapy: description, estimation and control. Raven, New York
Spector BD, Filipovich AH, Perry GS, Kersey JH (1982) Epidemiology of cancer in ataxia-telangiectasia. In: Bridges BA, Harnden DG (eds) Ataxia-telangiectasia – a cellular and molecular link between cancer, neuropathology and immune deficiency. Wiley, Chichester, pp 103–138
Taub R, Kirsch I, Morton C, Lenoir G, Swan D, Tronick S, Aaronson S, Leder P (1983) Transloca-tion of the c-myc gene into the immunoglobulin heavy chain locus in human Burkitt’s lymphoma and murine plasmacytoma cells. Proc Nat Acad Sci USA 79:7837–7841
Thein SL, Oscier DG, Flint J, Wainscoat JS (1986) Ha-ras hypervariable alleles in myelodysplasia. Nature 321:84–85
Thorgeirsson SS, Nebert DW (1977) The AL locus and the metabolism of chemical carcinogens and other foreign compounds. Adv Cancer Res 25:149–194
Waterhouse J, Muir C, Correa P, Powell J, Davies W (1976) Cancer incidence in five continents. IARC scientific publication 5. International Agency for Research on Cancer, Lyon
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1987 Springer-Verlag Berlin Heidelberg
About this paper
Cite this paper
Harnden, D.G. (1987). Genetic Predisposition for Cancer Risks in Man. In: Bannasch, P. (eds) Cancer Risks. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-71843-4_1
Download citation
DOI: https://doi.org/10.1007/978-3-642-71843-4_1
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-540-17465-3
Online ISBN: 978-3-642-71843-4
eBook Packages: Springer Book Archive